VK2735 for Weight Management Phase 2 (Venture Oral Dosing)
NCT ID: NCT06828055
Last Updated: 2025-10-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
280 participants
INTERVENTIONAL
2024-12-18
2025-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
VK2735 or matched placebo will be administered once daily.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
VK2735 for Weight Management Phase 2
NCT06068946
VK2735 for Weight Management Phase 3
NCT07104500
Phase 1 Study to Evaluate the Safety and Tolerability of VK2735
NCT05203237
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
NCT06717425
A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults
NCT00563368
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo Assignment
VK2735 (Placebo) administered Daily
Placebo
Matching Placebo to VK2735
Active Assignment (Dose #1)
VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
VK2735
Active Treatment
Active Assignment (Dose #2)
VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
VK2735
Active Treatment
Active Assignment (Dose #3)
VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
VK2735
Active Treatment
Active Assignment (Dose #4)
VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
VK2735
Active Treatment
Active Assignment (Dose #5)
VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
VK2735
Active Treatment
Active Assignment (Dose #6)
VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily
VK2735
Active Treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Matching Placebo to VK2735
VK2735
Active Treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI \<50 kg/m2
* Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.
* BMI calculated at the Screening visit will be used to determine eligibility.
Exclusion Criteria
2. Self-reported body weight change of 5% or more within 3 months of screening
3. Current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational)
4. Current or past diagnosis of chronic pancreatitis
5. Calcitonin ≥50 ng/L measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened)
6. Any GLP-1 receptor agonist or GLP-1/GIP dual agonist within 6 months of Screening
7. Any prescription or over-the-counter medications intended for weight loss within 6 months of screening
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Viking Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Viking Clinical Site #111
Peoria, Arizona, United States
Viking Clinical Site #105
Lake Forest, California, United States
Viking Clinical Site #101
Clearwater, Florida, United States
Viking Clinical Site #108
Largo, Florida, United States
Viking Clinical Site #107
Ocoee, Florida, United States
Viking Clinical Site #102
Port Orange, Florida, United States
Viking Clinical Site #100
Indianapolis, Indiana, United States
Viking Clinical Site #110
Louisville, Kentucky, United States
Viking Clinical Site #114
Marrero, Louisiana, United States
Viking Clinical Site #109
City of Saint Peters, Missouri, United States
Viking Clinical Site #112
Kansas City, Missouri, United States
Viking Clinical Site #113
Butte, Montana, United States
Viking Clinical Site #103
Knoxville, Tennessee, United States
Viking Clinical Site #104
Austin, Texas, United States
Viking Clinical Site #106
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VK2735-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.